The information presented in the figure below comes from a living network meta-analysis that combines all the available evidence on drug therapies for COVID-19. This statistical approach allows us to obtain estimates of effect for all potential comparisons, even those that have not been compared head-to-head in trials. We present the most trustworthy estimates of absolute effect for all available drug therapies for COVID-19 versus standard care. The colours distinguish between the most beneficial and harmful interventions compared to standard care, while the shading of cells indicates the certainty of the evidence of a particular drug based on the GRADE approach.
High/ moderate certainty
Low certainty
Very low certainty
No Evidence
Among the most
beneficial
Intermediate
benefit
Not convincingly
different
than standard care
Intermediate
harm
Among the most
harmful
Laboratory confirmed SARS-CoV-2 infection
|
Suspected, probable, or laboratory confirmed confirmed SARS-CoV-2 infection
|
Time to symptom resolution or clinical improvement
| ||||
---|---|---|---|---|---|---|
Baseline risk
|
65 per 1,000
|
77 per 1,000
|
3 per 1,000
|
0 per 1,000
|
22 per 1,000
|
---
|
Minimal important difference
|
20 per 1,000
|
30 per 1,000
|
10 per 1,000
|
1 per 1,000
|
20 per 1,000
|
1 day
|
ARGOVIT AgNPs
|
bamlanivimab
|
casirivimab, imdevimab
|
cilgavimab, tixagevimab
|
dimethyl sulfoxide nasal spray
|
hydroxychloroquine
|
hydroxychloroquine, tenofovir disoproxil fumarate/emtricitabine
|
iota-carrageenan
|
iota-carrageenan, ivermectin
|
ivermectin
|
lopinavir-ritonavir
|
melatonin
|
povidone-iodine
|
tenofovir disoproxil fumarate/emtricitabine
|
vitamin C
|
vitamin C, zinc
|
Laboratory confirmed SARS-CoV-2 infection | Suspected, probable, or laboratory confirmed confirmed SARS-CoV-2 infection | Admission to hospital**** | Mortality**** | Adverse effects leading to discontinuation**** | Time to symptom resolution or clinical improvement |
---|---|---|---|---|---|
-63 (-66 to -54)
|
0 (-17 to 17)
| ||||
-24 (-50 to 24)
|
-2 (-34 to 30)
| ||||
-53 (-62 to -40)
|
-72 (-78 to -59)
|
-3 (-34 to 28)
|
0 (-22 to 21)
|
0 (-2 to 1)
| |
-48 (-62 to -17)
|
-4 (-35 to 27)
|
-1 (-30 to 28)
| |||
-57 (-67 to -21)
| |||||
-10 (-28 to 10)
|
6 (2 to 10)
| ||||
-25 (-52 to 26)
|
-5 (-34 to 24)
|
34 (-13 to 81)
| |||
-51 (-65 to -9)
|
0 (-32 to 32)
|
0 (-30 to 30)
|
-5 (-27 to 17)
| ||
-56 (-65 to -36)
|
0 (-17 to 17)
| ||||
54 (-22 to 173)
|
-74 (-77 to -68)
|
-3 (-36 to 30)
|
-2 (-25 to 21)
| ||
-12 (-55 to 90)
|
-2 (-34 to 30)
| ||||
95 (-30 to 363)
|
0 (-33 to 33)
| ||||
-6 (-45 to 62)
|
-3 (-36 to 30)
|
-2 (-31 to 27)
|
20 (6 to 33)
| ||
-5 (-44 to 62)
|
-5 (-34 to 23)
|
46 (-2 to 94)
| |||
82 (-10 to 220)
|
-3 (-36 to 30)
|
-1 (-31 to 27)
|
46 (27 to 65)
| ||
-3 (-44 to 67)
|
-3 (-36 to 30)
|
-1 (-31 to 27)
|
69 (47 to 90)
|